VCAR33ALLO by Vor BioPharma for Refractory Acute Myeloid Leukemia: Likelihood of Approval

VCAR33ALLO is under clinical development by Vor BioPharma and currently in Phase II for Refractory Acute Myeloid Leukemia.

Related Keywords

Massachusetts ,United States ,Cambridge ,Cambridgeshire ,United Kingdom , ,Company Profile ,Company Profiles ,Puretech Health Plc ,Vor Biopharma ,Refractory Acute Myeloid ,Refractory Acute Myeloid Leukemia ,Treatment System ,